The Gonorrhea Therapeutics Market to Show Slow Growth until 2019

London, England -- (SBWire) -- 03/22/2012 --GlobalData forecasts that the global gonorrhea therapeutics market will grow at a Compound Annual Growth Rate (CAGR) of 7.4% over the next eight years to reach $13.7m by 2019. GlobalData’s analysis shows that the global Gonorrhea therapeutics market stood at $4.0m in 2006 and grew at a Compound Annual Growth Rate (CAGR) of 14.1% to reach $7.7m in 2011. The major reason for the fast growth in the historic period is the change in treatment pattern of the disease, such as the usage of cephalosporin antibiotics or combination therapies rather than the monotherapy. The change in treatment pattern was due to alteration in the susceptibility of Neisseria gonorrhea (N. gonorrhoeae) to various antibiotics used for treatment during the historic period. The antibiotics currently used for the treatment of gonorrhea are cephalosporins such as ceftriaxone, cefixime, cefpodoxime and cefoxitin. Other antibiotics such as azithromycin and doxycycline are also used in combination with cephalosporin for the treatment of gonorrhea. However, the patent protection of these antibiotics has expired and many generic versions are available at low prices, restricting the revenues of the market. Moreover, most of the antibiotics used for the treatment of gonorrhea are effective in a single dose, especially in the early stage of the disease, which further limits the gonorrhea therapeutic market.

Furthermore, there is no molecule present in the clinical investigation or at the discovery stage for the treatment of gonorrhea and the incidence rate of the disease is decreasing in the US each year. Thus, the gonorrhea market will remain highly genericized as well during the forecast period. The increasing usage of dual therapy such as cephalosporin plus azithromycin or cephalosporin plus doxycycline will drive the gonorrhea therapeutics market in the coming years.

GlobalData found that the current competition in the gonorrhea therapeutics market is weak because very few treatment options are available currently and there is evidence of a decrease in susceptibility of N. gonorrhoeae for the existing antibiotics. The antibiotics used for the treatment of gonorrhea are cephalosporins such as ceftriaxone, cefixime, cefpodoxime and cefoxitin. Other antibiotics such as azithromycin and doxycycline are also used in combination with cephalosporin for the treatment of gonorrhea.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages.aspx?ID=Gonorrhea-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&Title=Pharmaceuticals_and_Healthca&ReportType=Industry_Report&companyID=sbwire

The antibiotics from the class of fluoroqinolones such as ciprofloxacin, ofloxacin, levofloxacin and moxifloxacin were widely used during the last decade. But the use of these antibiotics decreased drastically in 2007 due to a decrease in the susceptibility of N. gonorrhoeae for these antibiotics. Since 2007, Cephalosporins were administered as a first line treatment for gonorrhea. Azithromycin or doxycycline was also given along with cephalosporin in some cases with dual infection of chlamydia and gonorrhea. Cephalosporins have good efficacy and safety profiles for the treatment of gonorrhea. However, increasing evidence of emergence of cephalosporin-resistant Gonorrhea has made the disease difficult to treat. In 2010, Centers for Disease Control and Prevention CDC included dual therapy(cephalosporin plus azithromycin or doxycycline) as a first-line treatment option for gonorrhea due to reported cases of resistance with monotherapy and an increase in the number of cases with dual infection of gonorrhea and chlamydia.

GlobalData, the industry analysis specialist, has released its new report, “Gonorrhea Therapeutics Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global gonorrhea therapeutics market. The report identifies the key trends shaping and driving the global gonorrhea therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global gonorrhea therapeutics market sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Gonorrhea-Therapeutics-Pipeline-Assessment-and-Market-Forecasts-to-2019&ReportType=Industry_Report&coreindustry=Industry_Report&Title=Pharmaceuticals_and_Healthca&companyID=sbwire

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com

North America:
+1 646 395 5477
Europe:
+44 207 753 4299
+44 1204 543 533
Asia Pacific:
+91 40 6616 6782